Side effects
Constipation on GLP-1 medication
How often constipation was recorded in the semaglutide, tirzepatide and oral semaglutide trials, in whom, and against the placebo arm of each.
This page is general information, not medical advice. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. A qualified clinician determines whether treatment is appropriate for you.
Generated from the family's dataset. No clinician has reviewed this page as a document.
What it is
Constipation appears in the gastrointestinal section of all three documents cited below, alongside diarrhea rather than instead of it.
The figure shown for tirzepatide is the highest-dose arm, which for this reaction is not the highest-rate arm in that label's table.
How often it was reported
The figures below come from the trials the branded products were approved on, and each one is shown against the placebo arm of the same trial. They describe the people in those studies — not anyone on this program, and not the compounded preparations this program dispenses.
The prescribing information for Wegovy lists constipation among the adverse reactions reported in the trials it was approved on. Measured in 24% of 2,116 adults taking 2.4 mg semaglutide weekly for 68 weeks, against 11% of 1,261 adults on placebo in the same trials. DailyMed, U.S. National Library of Medicine, 2026-06-30
The prescribing information for Zepbound lists constipation among the adverse reactions reported in the trials it was approved on. Measured in 11% of 941 adults taking 15 mg tirzepatide weekly for 72 weeks, against 5% of 958 adults on placebo in the same trials. DailyMed, U.S. National Library of Medicine, 2026-09-02
The prescribing information for Rybelsus lists constipation among the adverse reactions reported in the trials it was approved on. Measured in 5% of 356 adults with type 2 diabetes taking 14 mg oral semaglutide daily in placebo-controlled trials, against 2% of 362 adults with type 2 diabetes on placebo in the same trials. DailyMed, U.S. National Library of Medicine, 2026-08-19
What happens on this program
The refill check-in is the place to raise it, and you can reach your care team before then if you would rather not wait.
Anything you would take for it is worth mentioning to the prescribing clinician first, because that is a question about your prescription and not about this page.
When to get help
Everything above reports what those documents themselves list. None of it is a judgement about what is happening to you: nobody who wrote this page has seen you, and reading a page is not a consultation.
If something is happening and you are not sure what it means, contact your provider or the pharmacy that dispensed to you. If it is severe, or you think it may be an emergency, call 911 or go to the nearest emergency room.
The prescribing information for Wegovy directs a patient to tell a health care provider about any side effect that bothers them or that does not go away. DailyMed, U.S. National Library of Medicine, 2026-06-30